Independent · evidence-anchored—Reviewed by the GLPHelper Medical Team
EN·ES·For Providers ↗
glp·helper
Find a Provider →
glphelper.com/ozempic/california
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® Providers &
Prescriptions in California

Verified Ozempic providers across California. Checked against the NPI registry, sorted by waitlist — not by who pays us.[7]

state providers
384
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25–$1,150
monthly
01 / Find
stateCALIFORNIA
Search 384 results →
Filters: insurance, telehealth, waitlist, dose
§ 01Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes — and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4–1.8 percentage points and produced a mean weight loss of 4.5–6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy
§ 02Clinical evidence
N = 8,416 across SUSTAIN 1–7

What the trials actually showed.

We summarize results from the SUSTAIN program — the seven Phase III randomized trials Novo Nordisk submitted to the FDA — and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1–7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
§ 04Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15–20%), diarrhea (8–9%), and vomiting (5–9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15–20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8–9%
mild
More frequent during dose escalation
Vomiting
5–9%
mild
Reduced by slower titration
Constipation
3–7%
mild
Abdominal pain
5–7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 05Cost & coverage — published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 – $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 – $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
—
PA required; majority denied for weight indication
Medicare Part D
$0 – $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 – $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
§ 06Provider directory — California
21 of 21 shown

Find an Ozempic provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist — the provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /ozempic/california/{city}
Los Angeles
34.05°N
78 →
San Francisco
37.77°N
54 →
San Diego
32.71°N
49 →
Sacramento
38.58°N
32 →
San Jose
37.34°N
28 →
§ 07Frequently asked — Ozempic in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources — never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]